18 and older, any sex, with Pancreatic Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Disease Control Rate (DCR)Primary· Up to approximately 11 months from baseline
Percentage of patients with stable disease (SD), Complete Response (CR), or Partial Response (PR) for ≥16 weeks during treatment. Per RECIST v1.1, (CR): Disappearance of all target lesions. Any pathological lymph nodes (target or nontarget) with reduction in short axis to \<10 mm. (PR): ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease (PD): At least a 20% increas
Group
Value
95% CI
9-ING-41 Plus Retifanlimab Plus Gem/Abraxane
100
Best ResponseSecondary· Up to 12 months (from enrollment)
Number of patients with Complete Response (CR) or Partial Response (PR) or Stable Disease (SD) per RECIST v1.1 Per RECIST v1.1: Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (target or nontarget) with reduction in short axis to \<10 mm. Partial Response (PR): ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease (PD): At least a 2
Group
Value
95% CI
9-ING-41 Plus Retifanlimab Plus Gem/Abraxane
0
9-ING-41 Plus Retifanlimab Plus Gem/Abraxane
2
9-ING-41 Plus Retifanlimab Plus Gem/Abraxane
4
9-ING-41 Plus Retifanlimab Plus Gem/Abraxane
0
Overall Response Rate (ORR)Secondary· Up to 12 months (from enrollment)
Percentage of patients with Complete Response (CR) or Partial Response (PR) per RECIST v1.1 Per RECIST v1.1: Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (target or nontarget) with reduction in short axis to \<10 mm. Partial Response (PR): ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Group
Value
95% CI
9-ING-41 Plus Retifanlimab Plus Gem/Abraxane
33
Adverse Events and Serious Adverse EventsSecondary· Up to 12 months (from enrollment)
Number of participants with overall treatment-related adverse events (AE) and/or serious adverse events (SAE) at least possibly related as assessed by CTCAE v5.0.
Alanine aminotransferase increased
Group
Value
95% CI
9-ING-41 Plus Retifanlimab Plus Gem/Abraxane
2
Alopecia
Group
Value
95% CI
9-ING-41 Plus Retifanlimab Plus Gem/Abraxane
2
Anemia
Group
Value
95% CI
9-ING-41 Plus Retifanlimab Plus Gem/Abraxane
5
Anorexia
Group
Value
95% CI
9-ING-41 Plus Retifanlimab Plus Gem/Abraxane
1
Aspartate aminotransferase increased
Group
Value
95% CI
9-ING-41 Plus Retifanlimab Plus Gem/Abraxane
1
Ataxia
Group
Value
95% CI
9-ING-41 Plus Retifanlimab Plus Gem/Abraxane
1
Blurred vision
Group
Value
95% CI
9-ING-41 Plus Retifanlimab Plus Gem/Abraxane
1
Colitis
Group
Value
95% CI
9-ING-41 Plus Retifanlimab Plus Gem/Abraxane
1
Duration of Response (DOR)Secondary· Up to 12 months (from enrollment)
Time from documentation of tumor response to disease progression. Per RECISIT v1.1, Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (target or nontarget) with reduction in short axis to \<10 mm. Partial Response (PR): ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease (PD): At least a 20% increase in the sum
Group
Value
95% CI
9-ING-41 Plus Retifanlimab Plus Gem/Abraxane
5.273
4.862 – 5.684
Progression-free Survival (PFS)Secondary· Up to 12 months (from enrollment)
Time from study enrollment until objective tumor progression or death. Per RECISIT v1.1, Progressive Disease (PD) is ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.
Group
Value
95% CI
9-ING-41 Plus Retifanlimab Plus Gem/Abraxane
6.785481
4.970569 – 8.69
Overall Survival (OS)Secondary· Up to 24 months
Time patients are alive from study enrollment to death from any cause.
Group
Value
95% CI
9-ING-41 Plus Retifanlimab Plus Gem/Abraxane
10.72596
6.965337 – 20.40549
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse Events data collected for up to 12 months. All-Cause Mortality data collected for up to 24 months.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This trial examines how Pancreatic Adenocarcinoma reacts to the addition of 9-ING-41 and retifanlimab to the standard of care chemotherapy treatment, to see if using this combination will help and is able to effect disease progression.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
Other recruiting trials for Pancreatic Adenocarcinoma
Currently open trials in the same condition.
NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
· Phase 2
· recruiting
NCT07488676 — A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
· Phase 1, PHASE2
· recruiting
NCT07493421 — To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating P
· NA
· recruiting
NCT06896188 — 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLE
· Phase 1
· recruiting
NCT07090499 — A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
· Phase 1
· recruiting
Other Anwaar Saeed trials
Trials by the same sponsor.
NCT06896188 — 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLE
· Phase 1
· recruiting
NCT06698250 — Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
· Phase 2
· recruiting
NCT06006923 — Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer
· Phase 2
· terminated
NCT03539822 — Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointes
· Phase 1, PHASE2
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Anwaar Saeed
Last refreshed: 17 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05239182.